LifeMD (NASDAQ:LFMD) Sets New 12-Month High - Should You Buy?

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report)'s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as $12.19 and last traded at $12.01, with a volume of 767917 shares. The stock had previously closed at $11.53.

Wall Street Analyst Weigh In

Several analysts have issued reports on LFMD shares. HC Wainwright reissued a "buy" rating and issued a $14.00 price target on shares of LifeMD in a research note on Wednesday, April 30th. Cantor Fitzgerald reiterated an "overweight" rating and set a $15.00 price target on shares of LifeMD in a report on Tuesday, March 11th. Finally, B. Riley upgraded LifeMD to a "strong-buy" rating in a report on Tuesday, March 11th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $11.00.

LifeMD Price Performance

The company has a market capitalization of $552.19 million, a price-to-earnings ratio of -18.98 and a beta of 2.22. The business's 50-day moving average price is $7.42 and its two-hundred day moving average price is $6.28.

LifeMD (NASDAQ:LFMD - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.05. The firm had revenue of $65.70 million for the quarter, compared to analyst estimates of $62.47 million. As a group, research analysts predict that LifeMD, Inc. will post -0.56 EPS for the current year.

Insider Buying and Selling at LifeMD

In related news, CMO Jessica Friedeman sold 30,000 shares of the business's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $5.66, for a total value of $169,800.00. Following the sale, the chief marketing officer now owns 170,000 shares of the company's stock, valued at $962,200. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Justin Schreiber sold 50,000 shares of the business's stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $7.78, for a total transaction of $389,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,575,721 shares in the company, valued at approximately $20,039,109.38. This represents a 1.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 101,995 shares of company stock worth $724,422 over the last three months. Corporate insiders own 15.97% of the company's stock.

Institutional Trading of LifeMD

Several institutional investors have recently modified their holdings of LFMD. GAMMA Investing LLC bought a new stake in LifeMD during the first quarter valued at $35,000. CWM LLC boosted its position in LifeMD by 17.5% during the first quarter. CWM LLC now owns 9,050 shares of the company's stock valued at $49,000 after acquiring an additional 1,351 shares during the last quarter. ProShare Advisors LLC bought a new stake in LifeMD during the fourth quarter valued at $51,000. Balyasny Asset Management L.P. bought a new stake in LifeMD during the fourth quarter valued at $52,000. Finally, Oxford Asset Management LLP bought a new stake in LifeMD during the fourth quarter valued at $52,000. Institutional investors own 35.52% of the company's stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.